Kernal Biologics Joins NVIDIA Inception Program
CAMBRIDGE, Mass., August 26, 2025 - Kernal Bio, a venture-backed TechBio company pioneering novel therapeutics to program human cells directly inside the body, today announced its acceptance to the NVIDIA Inception Program. This NVIDIA initiative supports cutting-edge startups advancing AI, data science, and high-performance computing.
Kernal Bio's platform leverages AI models to unlock scalable in vivo treatments for cancer and autoimmune diseases. Through this collaboration, Kernal Bio gains access to NVIDIA’s technical expertise, software platforms, and high-performance GPU infrastructure — enabling the company to accelerate innovation in areas such as machine learning model development and integrated multi-omics data analysis.
“We developed KernaLM™, our LLM for mRNA design, which outperforms current state-of-the-art models. Leveraging NVIDIA’s powerful tools and computational resources will allow us to expand the capabilities of our AI-driven solutions, driving greater efficiency and insights for life sciences research,” said Jeff Ozdemir, PhD, Head of Platform at Kernal Bio.
As a member of NVIDIA Inception, Kernal Bio will benefit from:
Advanced AI Tools: Access to platforms such as NVIDIA RAPIDS and NVIDIA BioNeMo to accelerate data analysis speed and accuracy.
Cloud Resources: Scalable, on-demand infrastructure designed to support increasing computational workloads
Training and Expertise: Access to workshops and technical guidance to keep Kernal Bio at the forefront of AI innovation.
Networking Opportunities: Collaboration with a global network of AI startups, researchers, investors, and industry leaders.
By joining NVIDIA Inception, Kernal Bio strengthens its position as a leader in applying AI to the life sciences, committed to delivering efficient, cost-effective, and transformative therapeutics for patients worldwide. “We are thrilled to join the NVIDIA Inception Program,” noted Yusuf Erkul, MD, MBA, CEO of Kernal Bio.
About Kernal Biologics, Inc.
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. With support from leading investors—including Hummingbird Ventures, Amgen Ventures, Y Combinator, and HBM—Kernal Bio is transforming the future of cell therapy design and delivery. For more information, please visit our website at kernalbio.com. You can also connect with us on LinkedIn and X.
CONTACT:
+1(857) 370-0794